New Partnership Aims to Accelerate XLRS Gene Therapy Development
For individuals and families affected by inherited retinal diseases (IRDs), particularly X-linked retinoschisis (XLRS), news of advancements in gene therapy research offers significant hope. A recent strategic partnership between Avista Therapeutics and Forge Biologics is set to accelerate the development and manufacturing of AVST-101, Avista's lead gene therapy candidate for XLRS. This collaboration is a crucial step in bringing potential new treatments closer to the XLRS community, who currently have no approved therapies.
Key Details of the Collaboration
Avista Therapeutics, a biotechnology company focused on gene therapies for rare ophthalmic conditions, has teamed up with Forge Biologics, a genetic medicines manufacturer. The partnership centers on Avista's gene therapy candidate, AVST-101, which is designed to treat XLRS. XLRS is a genetic condition that primarily affects males, causing progressive vision loss, often starting in childhood.
Under this agreement, Forge Biologics will provide critical services including process development, cGMP (current Good Manufacturing Practices) manufacturing, toxicology support, and analytical development for AVST-101. These activities will take place at Forge's 200,000-square-foot gene therapy development and manufacturing facility, known as The Hearth, located in Columbus, Ohio.
AVST-101 is described as a next-generation gene therapy, incorporating advanced capsid engineering, efficient intravitreal (into the eye) delivery, low-dose efficacy, and broad retinal coverage. The goal of this innovative approach is to provide a potentially safer and more accessible treatment option for patients living with XLRS.
What This Means for Patients and Families
This partnership signifies a dedicated effort to overcome manufacturing challenges often associated with advanced therapies, which can be a bottleneck in bringing treatments to patients. By leveraging Forge's expertise in AAV (adeno-associated virus) manufacturing and proprietary technologies, Avista aims to streamline the production process for AVST-101. Robert Lin, PhD, CEO of Avista Therapeutics, stated that Forge's manufacturing expertise and platform technologies provide confidence in the development path for AVST-101.
Currently, there are no approved treatments for XLRS, a condition that affects approximately 30,000 males in the United States and the European Union. The development of AVST-101, with its focus on intravitreal delivery, aims to target specific retinal cell types with reduced dosages, potentially offering a less invasive treatment option.
Looking Forward
This collaboration represents a step forward in the journey to develop effective treatments for XLRS. The focus on robust manufacturing and advanced delivery methods for AVST-101 indicates a commitment to addressing the urgent needs of patients with this inherited retinal disease. The progress of this partnership will be closely watched by the IRD community as it moves towards potentially transformative gene therapies.